Skip to main content
. 2018 Jan 4;50(4):1294–1303. doi: 10.4143/crt.2017.512

Fig. 4.

Fig. 4.

(A) Progression-free survival (PFS) of first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) versus T790M mutation status of rebiopsy by Kaplan-Meier survival curve analysis. (B) PFS of first-line EGFR-TKI versus T790M mutation status of rebiopsy and baseline EGFR mutation status by Kaplan-Meier survival curve analysis.